These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20227757)

  • 1. Antisense technology to lower LDL cholesterol.
    Neely RD; Bassendine MF
    Lancet; 2010 Mar; 375(9719):959-61. PubMed ID: 20227757
    [No Abstract]   [Full Text] [Related]  

  • 2. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043021
    [No Abstract]   [Full Text] [Related]  

  • 5. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.
    Agarwala A; Jones P; Nambi V
    Curr Atheroscler Rep; 2015 Jan; 17(1):467. PubMed ID: 25398643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 10. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to managing the 'statin-intolerant' patient?
    Kohli P; Cannon CP
    Eur Heart J; 2012 May; 33(9):1040-3. PubMed ID: 22507980
    [No Abstract]   [Full Text] [Related]  

  • 15. [Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].
    MMW Fortschr Med; 2003 May; 145(20):59. PubMed ID: 12822234
    [No Abstract]   [Full Text] [Related]  

  • 16. Mipomersen and its use in familial hypercholesterolemia.
    Parham JS; Goldberg AC
    Expert Opin Pharmacother; 2019 Feb; 20(2):127-131. PubMed ID: 30526168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia.
    Brown WV; Rader DJ; Goldberg AC
    J Clin Lipidol; 2014; 8(1):10-7. PubMed ID: 24528683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
    Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Eichhorn EJ
    N Engl J Med; 2008 Jul; 359(5):529-30; author reply 532. PubMed ID: 18677795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.